13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002104501
Total reported value
$451.6M
$451.6M
6 檔
69.3%
During the Q1 2026 filing period, Remedium Capital Partners, LLC (CIK: 0002104501) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $451.6M across 6 reported positions.
In Q1 2026, Remedium Capital Partners, LLC displayed an active expansion posture, initiating 0 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SYRE | Spyre Therapeutics Inc | Stock-Other | 30.09% | +2.65% | +30.98% | |
| 2 | ORKA | Oruka Therapeutics Inc | Stock-Other | 28.98% | +5.68% | +21.69% | |
| 3 | DMRA | Damora Therapeutics Inc | Stock-Other | 16.57% | -7.06% | +1597.87% | |
| 4 | APGE | Apogee Therapeutics Inc | Stock-Other | 15.36% | -0.23% | — | |
| 5 | JBIO | Jade Biosciences Inc | Stock-Other | 6.93% | -0.12% | — | |
| 6 | ✓ | Crescent Biopharma Inc. | Stock-Other | 2.08% | -2.36% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DMRA | Damora Therapeutics Inc | +17.2% | +1597.87% | Add |
| 2 | ✓ | Crescent Biopharma Inc. | -0.2% | — | Unchanged |
| 3 | ORKA | Oruka Therapeutics Inc | -0.3% | +0.85% | Add |
| 4 | SYRE | Spyre Therapeutics Inc | -1.9% | — | Unchanged |
| 5 | JBIO | Jade Biosciences Inc | -6.4% | — | Unchanged |
| 6 | APGE | Apogee Therapeutics Inc | -8.4% | — | Unchanged |
According to official SEC Form 13F filings, Remedium Capital Partners, LLC reported a total U.S. public equity portfolio value of $451.6M across 6 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SYRE, ORKA, DMRA) accounted for 69.3% of total reported equity market value during Q1 2026.
During Q1 2026, Remedium Capital Partners, LLC's top holdings by market value included SYRE (30.1%)、ORKA (29.0%)、DMRA (16.6%). The largest single position, SYRE, represented 30.1% of total portfolio value.
In Q1 2026, Remedium Capital Partners, LLC made 2 total portfolio adjustments, initiating 0 new buys, adding to 2 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.